Dose-dependent efficacy of miglitol, an α-glucosidase inhibitor, in Type 2 diabetic patients on diet alone: Results of a 24-week double-blind placebo-controlled study

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 15, Issue 3, 2002, Pages 152-159

  Drent, M L ^a   Tollefsen, A T M ^a   van Heusden, F H J A ^a   Hoenderdos, E B M ^a   Jonker, J J C ^a   van der Veen, E A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

glucosidase inhibition; Dose dependency; Miglitol; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIGUANIDE; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MIGLITOL; PLACEBO; SULFONYLUREA; ALPHA GLUCOSIDASE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSAMINE; GLYCOSYLATED HEMOGLOBIN; IMINOSUGAR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FOOD; GASTROINTESTINAL DISEASE; MIDDLE AGED;

AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FOOD; GASTROINTESTINAL DISEASES; GLUCOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGE; PLACEBOS; DIABETES MELLITUS, TYPE 2; HUMANS; IMINO PYRANOSES; MIDDLE AGED;

EID: 0036319032     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. The effect of miglitol and acarbose after an oral glucose load: A novel hypoglycaemic mechanism?
2. Chronic treatment of African-American type 2 diabetic patients with a-glucosidase inhibition
3. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients
4. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone
5. Effects of the carbohydrase inhibitor miglitol in sulfonurea-treated NIDDM patients
6. α-Glucosidase inhibition by miglitol in NIDDM patients
7. Long-term titrated-dose α-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients
8. Long-term effectiveness of a new α-glucosidase inhibitor (BAY m 1099-miglitol) in insulin-treated type 2 diabetes mellitus
9. Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus
10. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes
11. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man
12. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers
13. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance
14. Does suppression of postprandial blood glucose excursions by the (α)-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
15. Reduction of postprandial blood glucose by the α-glucosidase inhibitor miglitol (Bay m 1099) in type II diabetes
16. Nutritional recommendations and principles for individuals with diabetes mellitus: 1986
17. Nutritional recommendations for individuals with diabetes mellitus
18. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone
19. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
20. Carbohydrate malabsorption following acarbose administration